Simon Hughes PN D
While the full protocol details are not publicly available in their entirety, the registration demonstrates a commitment to generating real clinical evidence, something most supplement companies never do
We build plans that fit your schedule, budget, and health needs
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
By comparison, a company like 1st Optimal offers a host of additional testing and prescription services in the face of side effects most commonly associated with its standard treatments
T2DM patients experienced a 15% reduction in their IL-6 levels after taking liraglutide [28]